

ONE HUNDRED THIRTEENTH CONGRESS
Congress of the United States
House of Representatives

COMMITTEE ON ENERGY AND COMMERCE

2125 RAYBURN HOUSE OFFICE BUILDING
WASHINGTON, DC 20515-6115

Majority (202) 225-2927
Minority (202) 225-3641

August 13, 2013

Dr. Kasey K. Thompson, PharmD, MS
Vice President
Planning and Communication
American Society of Health-System Pharmacists
7272 Wisconsin Avenue
Bethesda, MD 20814

Dear Dr. Thompson:


Thank you for appearing before the Subcommittee on Health on Tuesday, July 16, 2013, to testify at the hearing entitled "Reforming the Drug Compounding Regulatory Framework."

During the hearing, Members asked you to provide additional information for the record, and those requests are attached. The format of your responses to these questions should be as follows: (1) the name of the Member whose request you are addressing, (2) the complete text of the request you are addressing in bold, and (3) your response to that request in plain text.

To facilitate the printing of the hearing record, please respond to these questions and requests by the close of business on Tuesday, August 27, 2013. Your responses should be mailed to Sydne Harwick, Legislative Clerk, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, D.C. 20515 and e-mailed in Word format to Sydne.Harwick@mail.house.gov.

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,



Joseph R. Pitts
Chairman
Subcommittee on Health

cc: The Honorable Frank Pallone, Jr., Ranking Member, Subcommittee on Health

Attachment

Attachment —Member Requests for the Record

During the hearing, Members asked you to provide additional information for the record and you indicated that you would provide that information. For your convenience, descriptions of the requested information are provided below.

The Honorable John D. Dingell

1. Do you believe that it is important to have clear lines of division between FDA and State boards of pharmacy when it comes to regulating compounding pharmacies? Please elaborate.
2. In your testimony, you mention that your members also use compounded sterile preparations which are not available in an appropriate form from a manufacturer. Is this correct? Would you please submit a list of examples of these kinds of products?
3. Does Section 503(a), as currently drafted and interpreted, recognize the existence of these compounding outsourcers and our reliance on them? Please elaborate.